NuVasive to acquire Osiris unit

05/8/2008 | Houston Chronicle (tiered subscription model)

NuVasive will purchase Osteocol, a subsidiary of Osiris Therapeutics, in a deal that allows it to gain access to the unit's developing stem cell technology and expand into the biotech market. The acquisition, which will close in the third quarter, includes $35 million in cash and future milestone payments to Osiris worth up to $50 million.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA